Guided by a commitment to patient care, the Elahi Lab leverages clinical insights to design laboratory research for discovery of therapeutically targetable links between disease of the brain’s vascular system with neurodegeneration.

We aim to cure dementia by understanding the role of blood vessels in human brain function and the genetic causes of vascular pathology across the lifespan that may cause a spectrum of dementia-related diseases. With a focus on making translational impact, the Elahi Lab’s multidisciplinary approach combines deep clinical, cellular, and molecular phenotyping to model disease, identify early biomarkers and find therapeutic targets for vascular brain dysfunction and degeneration.

We seek to understand how these genetic variations relate to brain aging and modify risk for the development of disease. The two genes we are currently focused on are:

  • NOTCH3: associated with CADASIL (Cerebral Autosomal Dominant Arteriopathy Subcortical Infarcts and Leukoencephalopathy)
  • APOE4: the most prevalent genetic risk factor for Alzheimer’s Disease

By developing novel tools that quantitatively capture blood vessel disease and its links to brain dysfunction —and by prioritizing human research samples—we hope to make breakthrough discoveries that will help people living with Alzheimer’s, Parkinson’s, CADASIL, frontotemporal dementia, and other neurodegenerative diseases.


Please reach out if you are interested in participating in our research and have been diagnosed with any of the following:

  • CADASIL or another genetic vascular disease
  • White matter disease on brain imaging
  • Vascular cognitive impairment 

We also invite healthy individuals and caretakers to participate in our study as a healthy control.

To see if you qualify, please get in touch with our clinical research coordinator, Ryan Park at

Send a Message Now
Support Our Research